Yeah it's pretty crazy how close this company was to becoming a $20-50 stock a few years ago with BoM. A little more power for the study, or just excluding stroke maybe. 

In any event BoM2 looks stacked much better in our favor. 

But perhaps Covid beats BoM2 to the punch.

And combined with the future outlook of the Covid proof plus the BTD, BoM2 and PAH looming plus other opportunities, gets us to the end zone. Exciting times again, but can we actually get it done and hit our end points finally??

And I do also agree, the benefit to our people is exciting as much as the financial opportunity. Not a spring chicken anymore, myself.

We should have a good idea in the next few months. Good luck to all!